Innovation meets compliance.
Precise, consistent dosing.
UpCard-CA1 should be administered at 0.05 to 0.2 mg/lb. (0.11 to 0.44 mg/kg) of bodyweight once daily.1
With UpCard-CA1, there’s no over or underdosing.
Comparison of dosing a dog weighing 18 lbs. – a common weight for dogs with CHF.2
UpCard-CA1 helps pet owners manage treatment easier.
When managing the complexity of giving pills two to three times a day, choosing UpCard-CA1 gives veterinarians and their clients the benefit of a once daily, easily titratable oral solution.
UpCard-CA1 is conditionally approved by the FDA pending a full demonstration of effectiveness under application number 141-577. It is a violation of Federal law to use this product other than as directed in the labeling.
IMPORTANT SAFETY INFORMATION: UpCard-CA1 is for use in dogs only. Do not administer to dogs with renal failure, anuria, severe dehydration, hypovolemia, or hypotension. Do not administer UpCard-CA1 concomitantly with other loop diuretics or to dogs with hypersensitivity to the active substance, torsemide, or to any of the excipients. UpCard-CA1 should be used only in stable dogs with congestive heart failure caused by MMVD which has been diagnosed by means of a comprehensive physical and cardiac examination. This drug has not been evaluated in dogs used for breeding, pregnant, or lactating bitches. The most common side effects seen in dogs with CHF due to MMVD while taking UpCard-CA1 are cough, dyspnea, pulmonary edema, and cardiac arrest. Adverse reactions not related to disease progression in dogs receiving UpCard-CA1 include polyuria and polydipsia, renal insufficiency, increased BUN and serum creatinine, urinary incontinence, hypokalemia, hypochloremia, hypercalcemia, hypomagnesemia, diarrhea, vomiting, and inappetence. For full prescribing information, visit vetoquinolusa.com/upcard-ca1-info.
References
1UpCard-CA1 Product label.
2Data on file.
3Besche B, et al. Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study. J Vet Intern Med. 2020;34(5):1746–1758.
